Skip to main content

Table 1 Patient Characteristics

From: Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

Patient Characteristics Prospective Data
n = 100 (%)
Retrospective Data
n = 85 (%)
Total Cohort
n = 185 (%)
Sex:    
   Males 75 (75%) 68 (80%) 143 (77%)
   Females 25 (25%) 17 (20%) 42 (23%)
Median age (years) 66(32–88) 68 (45–84) 68 (32–88)
Mean age 66 67 67
Staging:    
   Stage IIIB (effusion) 37 (37%) 29 (34%) 66 (36%)
   Stage IV 63 (63%) 56 (66%) 119 (64%)
Histological Subtype:    
   Large cell carcinoma 50 (50%) 28 (33%) 78 (42%)
   Adenocarcinoma 36 (36%) 31 (36%) 67 (36%)
   Squamous cell carcinoma 10 (10%) 13 (15%) 23 (12%)
   Bronchoalveolar 2 (2%) 4 (5%) 6 (3%)
   Undifferentiated carcinoma 2 (2%) 4 (5%) 6 (3%)
   Mixed 0 (0%) 2 (2%) 2 (1%)
   Not available 0 (0%) 3 (3.5%) 3 (2%)
Measurable disease 88 (88%) 82 (96%) 170 (92%)
Evaluable disease 4 (4%) 2 (2%) 6 (3%)
Non-measurable disease 8 (8%) 1 (1%) 9 (5%)
ECOG Performance Status:    
   ECOG 0 28 (28%) 17 (20%) 45 (24%)
   ECOG 1 35 (35%) 26 (30.5%) 61 (33%)
   ECOG 2 23 (23%) 15 (18%) 38 (20.5%)
   ECOG 3 & 4 14 (14%) 20 (23%) 34 (19%)
   Not available 0 (0%) 7 (8%) 7 (4%)
Estimated life expectancy:    
   <12 weeks 34 (34%) 20 (23.5%) 54 (29%)
   >12 weeks 66 (66%) 58 (68%) 124 (67%)
   Not available 0 (0%) 7 (8%) 7 (4%)
Weight loss > 10% in 6 weeks 26 (26%) 26 (30.5%) 52 (28%)
Weight loss Not available 0 (0%) 10 (12%) 10 (5%)
Incapable of giving informed consent 1 (1%) 3 (3.5%) 4 (2%)
  1. * retrospective patients were added to the Medical Oncology department referral base
  2. # Blood abnormalities leading to exclusion from SWOG lung trial